. Detection of ductal carcinoma in situ in women undergoing screening mammography . J Natl Cancer Inst 2002 ; 94 : 1546 – 1554 . 65 Page DL Dupont WD Rogers LW Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade
Search Results
An Overview of Mammography: Benefits and Limitations
Robert A. Smith
Spine Radiosurgery in the Management of Renal Cell Carcinoma Metastases
Neil K. Taunk, Daniel E. Spratt, Mark Bilsky, and Yoshiya Yamada
Identify those patients with metastatic RCC who may benefit the most from SRS treatment Renal Cell Carcinoma and the Case for Local Therapy for Metastatic Disease Renal cell carcinoma (RCC) is the seventh most common malignancy in the United
Optimal Management of Localized Renal Cell Carcinoma: Surgery, Ablation, or Active Surveillance
David Y. T. Chen and Robert G. Uzzo
Edited by Kerrin G. Robinson
: casting doubt on the efficacy of early intervention . Urology 2001 ; 57 : 1013 – 1015 . 3 Hollenbeck BK Taub DA Miller DC . National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology
Evaluation and Management of the Unknown Primary Carcinoma of the Head and Neck
Chad E. Galer and Merrill S. Kies
in the management of unknown primary head and neck carcinoma . Arch Otolaryngol Head Neck Surg 2005 ; 131 : 626 – 629 . 2. Califano J Leong PL Koch WM . Second esophageal tumors in patients with head and neck squamous cell carcinoma: an
Integrating Immunotherapy Into the Management of Renal Cell Carcinoma
Matthew Zibelman and Elizabeth R. Plimack
carcinoma (RCC), a cancer long considered “immunogenic,” is a prominent example. In the 1960s, cases of spontaneous remissions in patients with metastatic RCC (mRCC) were reported, documenting a curious phenomenon unique to few metastatic tumors and
BRAF Inhibition in BRAF V600E-Positive Anaplastic Thyroid Carcinoma
Annette M. Lim, Graham R. Taylor, Andrew Fellowes, Laird Cameron, Belinda Lee, Rodney J. Hicks, Grant A. McArthur, Christopher Angel, Benjamin Solomon, and Danny Rischin
effective treatments available. For tumors that harbor known targetable mutations, treatments directed at those mutations can be highly effective and well tolerated. 1 , 2 Anaplastic thyroid carcinoma (ATC) is an uncommon, highly aggressive tumor with a
Diagnostic Delays Are Common Among Patients With Hepatocellular Carcinoma
Nishant Patel, Adam C. Yopp, and Amit G. Singal
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Although its incidence is lower in the United States and Europe, its incidence is rapidly increasing because of a growing number of cases of nonalcoholic
Merkel Cell Carcinoma Guidelines
Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The mortality rate of MCC exceeds that of melanoma, and the 5-year disease-specific survival rate is 64%. These guidelines and most biomedical literature suggest that the workup of a patient with MCC should include chest radiograph and additional studies as clinically indicated. These guidelines, which the NCCN Non-Melanoma Skin Cancer Panel developed as a supplement to those for squamous cell and basal cell skin cancer, also outline treatment strategies.
For the most recent version of the guidelines, please visit NCCN.org
Prostate Cancer Early Detection, Version 2.2015
Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenke, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah Freedman-Cass
. Individual Disclosures of the NCCN Merkel Cell Carcinoma Panel References 1. Siegel RL Miller KD Jemal A . Cancer statistics, 2015 . CA Cancer J Clin 2015 ; 65 : 5 – 29 . 2. National Cancer Institute . Surveillance
Can Therapy of Hepatitis C Affect the Development of Hepatocellular Carcinoma?
Laura M. Kulik
. Coussens LM Werb Z . Inflammation and cancer . Nature 2002 ; 420 : 860 – 867 . 2. Llovet JM Burroughs A Bruix J . Hepatocellular carcinoma . Lancet 2003 ; 362 : 1907 – 1917 . 3. Bosch FX Ribes J Diaz M . Primary liver cancer
